Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

• Published in: Blood Vol. 98; no. 3; pp. 548 - 553
• Main Authors: Stone, Richard M., Berg, Deborah T., George, Stephen L., Dodge, Richard K., Paciucci, Paolo A., Schulman, Philip P., Lee, Edward J., Moore, Joseph O., Powell, Bayard L., Baer, Maria R., Bloomfield, Clara D., Schiffer, Charles A.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.08.2001; The Americain Society of Hematology
• Subjects: Actuarial Analysis; Acute Disease; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; Cytarabine - administration & dosage; Cytarabine - standards; Cytarabine - toxicity; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Leukemia, Myeloid - complications; Leukemia, Myeloid - drug therapy; Medical sciences; Middle Aged; Mitoxantrone - administration & dosage; Mitoxantrone - standards; Mitoxantrone - toxicity; Pharmacology. Drug treatments; Remission Induction; Survival Rate; Time Factors; Treatment Outcome; Human; Antineoplastic agent; Drug combination; Anthraquinone derivatives; Acute; Malignant hemopathy; Posology; Alkylating agent; Chemotherapy; Cytarabine; Antimetabolic; Maintenance treatment; Clinical trial; Remission; Mitoxantrone; Therapeutic protocol; Elderly; Pyrimidine nucleoside; Age; Acute myelocytic leukemia

The treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and long-term disease-free survival in 10% to 20%. Three hundred eighty-eight patients (60 years of age and older) with newly diagnosed de novo AM...